| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2026-03-09 |
| タイトル |
|
|
タイトル |
Medication Adherence and Antithrombotic Therapy Outcomes |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
キーワード |
atrial fibrillation |
| キーワード |
|
|
言語 |
en |
|
キーワード |
bleeding |
| キーワード |
|
|
言語 |
en |
|
キーワード |
coronary artery disease |
| キーワード |
|
|
言語 |
en |
|
キーワード |
medication adherence |
| キーワード |
|
|
言語 |
en |
|
キーワード |
monotherapy |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| アクセス権 |
|
|
アクセス権 |
open access |
| 著者 |
Chiba, Naoki
Noda, Takashi
Nochioka, Kotaro
海北, 幸一
WEKO
34072
e-Rad_Researcher
30346978
| ja |
海北, 幸一
宮崎大学
|
| ja-Kana |
カイキタ, コウイチ
|
| en |
Kaikita, Koichi
University of Miyazaki
|
Search repository
Akao, Masaharu
| en |
Akao, Masaharu（Personal）
National Hospital Organization Kyoto Medical Center
|
Search repository
Ako, Junya
Matoba, Tetsuya
Nakamura, Masato
Miyauchi, Katsumi
| en |
Miyauchi, Katsumi（Personal）
Juntendo Tokyo Koto Geriatric Medical Center
|
Search repository
Hagiwara, Nobuhisa
Kimura, Kazuo
Matsui, Kunihiko
Ogawa, Hisao
Yasuda, Satoshi
AFIRE Investigators
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Background
The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial demonstrated that rivaroxaban monotherapy has noninferior efficacy and superior safety compared with combination therapy (rivaroxaban plus a single antiplatelet) in patients with atrial fibrillation and stable coronary artery disease.
Objectives
This post hoc analysis aimed to explore the impact of medication adherence on the AFIRE trial results.
Methods
A total of 2,120 patients were categorized into adherent and nonadherent groups based on self-reported assessments, which were further validated through on-site visits to the facilities. Adherence was defined as continuous medication use as prescribed. The primary efficacy endpoint was a composite of stroke, systemic embolism, myocardial infarction, revascularization requiring unstable angina, or all-cause death. The primary safety endpoint was major bleeding events.
Results
Among the 2,012 (94.9%) adherent patients, rivaroxaban monotherapy showed significantly better outcomes compared with combination therapy regarding both efficacy (HR: 0.72; 95% CI: 0.53-0.96; P = 0.028) and safety (HR: 0.63; 95% CI: 0.41-0.97; P = 0.034). However, no significant differences in outcomes were shown in nonadherent patients (n = 108). There was no interaction between medication adherence and the randomized treatment group. In clinically high-risk patients with a history of angina pectoris, compared with nonadherent patients (n = 68), those who demonstrated medication adherence (n = 1,281) exhibited significantly better efficacy outcomes (HR: 0.52; 95% CI: 0.30-0.97; P = 0.041).
Conclusions
High adherence to rivaroxaban monotherapy was associated with improved outcomes, underscoring the importance of adherence in achieving optimal therapeutic effects (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease [AFIRE], NCT02642419; AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study, UMIN000016612). |
|
言語 |
en |
| 書誌情報 |
en : Jacc Asia
巻 6,
号 3,
p. 329-341,
発行日 2026-03
|
| 出版者 |
|
|
出版者 |
Elsevier BV |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
27723747 |
| DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.1016/j.jacasi.2025.11.018 |
| 権利 |
|
|
権利情報 |
© 2026 The Authors. |
|
言語 |
en |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
Fulltext (2.2 MB)
.png)
